Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + Intensive Chemotherapy in Newly Diagnosed AML With NPM1 Mutation
NCT07211958Phase 3Recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Revumenib + Intensive Chemotherapy with Placebo + Intensive Chemotherapy (2 arms). Primary endpoints: Event Free Survival up to 2 years and Measurable Residual Disease Complete Remission Rate up to 2 years. Started Nov 2025; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07211958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211958.